The U.S. veterinary oncology market size was exhibited at USD 101.97 million in 2023 and is projected to hit around USD 184.34 million by 2033, growing at a CAGR of 6.1% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 108.19 Million |
| Market Size by 2033 | USD 184.34 Million |
| Growth Rate From 2024 to 2033 | CAGR of 6.1% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Therapy, animal type |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | U.S. |
| Key Companies Profiled | Boehringer Ingelheim International GmbH; Elanco; Zoetis; PetCure Oncology; Accuray Incorporated; Varian Medical System, Inc; Morphogenesis, Inc.; Karyopharm Therapeutics, Inc.; Regeneus Ltd.; One Health |
The major contributors to the market growth are the increasing prevalence of cancer cases, the growing number of pet owners, technological advancements in per cancer therapeutics, and ongoing clinical trials related to veterinary oncology. Moreover, pet owners are willing to spend more on pet health, which is also among the major factors driving the demand for pet cancer therapies. The COVID-19 pandemic has changed pet owners’ relationships with their companions. It acted as a catalyst for rapid business and economic changes.
As various governments across the world urged individuals to stay at home during the pandemic, many people found comfort and companionship through pets. The pet expenditure has witnessed an increase during the coronavirus breakdown. At the animal shelters in the country, adoption rates soared as much as 40% in 2020 as compared to 2019. Growing R&D in veterinary oncology to provide the best treatments to pets with cancer is a major boon for the market. An increase in investments related to pet cancer therapeutics by organizations is expected to fuel the market growth. The corporations are engaging in strategies, such as licensing, R&D collaborations, and business development, to enhance their product pipeline in veterinary oncology.
For instance, in 2021, Boehringer Ingelheim spent USD 412 million on their R&D activities. Furthermore, ongoing clinical trials in this field support the market growth. In March 2022, The University of Illinois Cancer Care Clinic and Comparative Oncology Research Laboratory publicized two clinical trials for canine cancer. Other supportive drugs are still in pipeline and are expected to offer lucrative opportunities in the coming years. Veterinary medicine has evolved numerously in recent years and advancements in technology permit to provide medical attention to pets as it is available for humans.
Technological upgradation in the veterinary sector to provide an effective treatment to companion animals drives the market growth. In addition, the presence of major players in the country further contributes to its growth. Participants in the country are actively involved in product expansion strategies to gain a competitive advantage. For instance, in January 2021, CureLab Oncology started CureLab Veterinary, a subsidiary with exclusive rights to use CureLab Oncology patents for the treatment of canines, felines, and horses worldwide. The first target market for the subsidiary’s patented DNA therapeutics is canines and felines. The company also has seven R&D sites in the U.S.
The radiology segment accounted for the maximum share of more than 25% of the global revenue in 2023. Radiology is often carried out with surgery to help excise tumors. An increasing number of government initiatives for the establishment of new veterinary radiation centers in the U.S. are propelling the growth of this segment. For instance, in November 2020, at Roanoke, Virginia, Virginia Tech’s Animal Cancer Care and Research Center started a radiation therapy facility for pets that has a Varian LINAC accelerator installed. The LINAC also consists of Rapid Arc technology.
It can rotate 360 degrees while delivering the radiation to treat different types of tumors in companion animals. The establishment of such new state-of-the-art radiology centers focused on treatment for pet cancer is expected to help boost the segment growth. The immunotherapy segment, on the other hand, is expected to register the fastest growth rate of over 8% in the coming years on account of an increase in the number of veterinary centers focused on carrying out clinical trials in immunotherapy. For instance, The University of Pennsylvania in collaboration with Penn Vet Cancer Center is involved in carrying out immunotherapy clinical trials.
The canine segment held the largest revenue share of over 56% in 2023 and is also anticipated to grow the fastest in the coming years. The rising prevalence of canine cancer boosts the demand for an effective treatment modality. Increasing R&D initiatives and a growing number of clinical trials support the segment’s dominance. For instance, in November 2021, The UC Davis School of veterinary medicine became part of the Vaccination Against Canine Cancer Study (VACCS) trial, the largest clinical trial to evaluate a new vaccine strategy for the treatment and prevention of cancer in dogs. An increase in clinical trial activities specific to canine cancer therapeutics is expected to propel the segment growth in the coming years.
For instance, in March 2020, The Comparative Oncology Research Laboratory and the University of Illinois Cancer Care Clinic publicized 2 clinical trials for canines with cancer. Other supportive drugs are still in the pipeline and, if approved, can significantly drive the market. Cats are the second most popular choice by pet owners in the U.S. Increased concerns regarding their health and hygiene are driving the growth of the feline segment. According to the published article in NCBI in 2021, squamous cell carcinoma is the most common malignant oral tumor in the feline population. The growing number of cats diagnosed with cancer is expected to boost the demand for veterinary oncology products in the U.S.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. veterinary oncology market.
Therapy
Animal Type
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers